- Home
- PMO vs IMMP Comparison
PMO vs IMMP Comparison
Compare PMO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMO
- IMMP
- Stock Information
- Founded
- PMO 1993
- IMMP 1987
- Country
- PMO United States
- IMMP Australia
- Employees
- PMO N/A
- IMMP N/A
- Industry
- PMO Finance Companies
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- PMO Finance
- IMMP Health Care
- Exchange
- PMO Nasdaq
- IMMP Nasdaq
- Market Cap
- PMO 287.4M
- IMMP 211.1M
- IPO Year
- PMO N/A
- IMMP N/A
- Fundamental
- Price
- PMO $9.99
- IMMP $1.86
- Analyst Decision
- PMO
- IMMP Buy
- Analyst Count
- PMO 0
- IMMP 2
- Target Price
- PMO N/A
- IMMP $8.50
- AVG Volume (30 Days)
- PMO 99.0K
- IMMP 648.0K
- Earning Date
- PMO 01-01-0001
- IMMP 05-16-2025
- Dividend Yield
- PMO 4.10%
- IMMP N/A
- EPS Growth
- PMO N/A
- IMMP N/A
- EPS
- PMO 0.42
- IMMP N/A
- Revenue
- PMO N/A
- IMMP $3,019,249.00
- Revenue This Year
- PMO N/A
- IMMP $11.25
- Revenue Next Year
- PMO N/A
- IMMP $10.22
- P/E Ratio
- PMO $24.38
- IMMP N/A
- Revenue Growth
- PMO N/A
- IMMP 24.11
- 52 Week Low
- PMO $8.57
- IMMP $1.32
- 52 Week High
- PMO $10.68
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- PMO 55.88
- IMMP 53.43
- Support Level
- PMO $9.84
- IMMP $1.44
- Resistance Level
- PMO $10.03
- IMMP $2.71
- Average True Range (ATR)
- PMO 0.10
- IMMP 0.17
- MACD
- PMO 0.04
- IMMP 0.05
- Stochastic Oscillator
- PMO 100.00
- IMMP 29.75
About PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.